menu
    • menu
    [{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Adipic Acid Dihydrazide","moa":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ABVC BioPharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ABVC BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Adipic Acid Dihydrazide","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ABVC BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Hyaluronic Acid","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ABVC BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Adipic Acid Dihydrazide","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ABVC BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Adipic Acid Dihydrazide","moa":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ABVC BioPharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ABVC BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Adipic Acid Dihydrazide","moa":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ABVC BioPharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ABVC BioPharma \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for CAS-1071-93-8

    Menu

    CAS-1071-93-8

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ABVC BioPharma

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            ABVC BioPharma

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hyaluronic Acid Derived Therapy,Adipic Dihydrazide

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ABVC BioPharma Vitargus Phase II Study Received Ethical Approval at Sydney Eye Hospital in Australia

                            Details : ABV-1701 is a hyaluronic acid derived hydrogel therapy which is currently being investigated for the treatment of retinal detachment and vitreous hemorrhage.

                            Brand Name : ABV-1701

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 22, 2023

                            Lead Product(s) : Hyaluronic Acid Derived Therapy,Adipic Dihydrazide

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ABVC BioPharma

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            ABVC BioPharma

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hyaluronic Acid Derived Therapy,Adipic Dihydrazide

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ABVC BioPharma Provides Vitargus Update on Phase II Site Initiation Visit Conducted at Ramathibodi Hospital in...

                            Details : ABV-1701 is a hyaluronic acid derived hydrogel therapy which is currently being investigated for the treatment of retinal detachment and vitreous hemorrhage.

                            Brand Name : ABV-1701

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 06, 2023

                            Lead Product(s) : Hyaluronic Acid Derived Therapy,Adipic Dihydrazide

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            ABVC BioPharma

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            ABVC BioPharma

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hyaluronic Acid-derived Therapy,Adipic Dihydrazide

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ABVC BioPharma Provides Vitargus® Update - Phase II Vitargus® Study Protocol Received Thai FDA Approval

                            Details : Vitargus (hyaluronic acid-derived therapy) is a next-generation vitreous substitute that a First-In-Human clinical trial has demonstrated is a significant upgrade to current vitreous substitutes available to eye surgeons.

                            Brand Name : Vitargus

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 17, 2022

                            Lead Product(s) : Hyaluronic Acid-derived Therapy,Adipic Dihydrazide

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            ABVC BioPharma

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            ABVC BioPharma

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hyaluronic Acid,Adipic Dihydrazide

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ABVC BioPharma Announces Vitargus® Phase II Study Plan Approved by HREC in Australia

                            Details : ABV-1701 is an injectable, in-situ-forming hydrogel, composed of oxidized hyaluronic acid (oxi-HA) and adipic acid dihydrazide (ADH) and is used for the treatment of uncomplicated retinal detachment.

                            Brand Name : ABV-1701

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 05, 2022

                            Lead Product(s) : Hyaluronic Acid,Adipic Dihydrazide

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            ABVC BioPharma

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            ABVC BioPharma

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hyaluronic Acid-derived Therapy,Adipic Dihydrazide

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ABVC BioPharma Selects Additional Vitargus® Phase II Study Site

                            Details : Vitargus (Hyaluronic Acid Derived Therapy) is a next-generation vitreous substitute that a First-In-Human clinical trial has demonstrated is a significant upgrade to current vitreous substitutes available to eye surgeons.

                            Brand Name : Vitargus

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 09, 2022

                            Lead Product(s) : Hyaluronic Acid-derived Therapy,Adipic Dihydrazide

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            ABVC BioPharma

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            ABVC BioPharma

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hyaluronic Acid Derived Therapy,Adipic Dihydrazide

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ABVC BioPharma Provides Vitargus® Update

                            Details : Vitargus/ABV-1701 (hyaluronic acid derived therapy) is a next-generation vitreous substitute that a First-In-Human clinical trial has demonstrated is a significant upgrade to current vitreous substitutes available to eye surgeons.

                            Brand Name : ABV-1701

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 30, 2022

                            Lead Product(s) : Hyaluronic Acid Derived Therapy,Adipic Dihydrazide

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth